TEM

Tempus AI, Inc. Class A Common Stock

66.46 USD
-2.45
3.56%
Updated May 14, 1:51 PM EDT
1 day
-3.56%
5 days
13.96%
1 month
54.09%
3 months
-25.69%
6 months
17.36%
Year to date
94.04%
1 year
65.12%
5 years
65.12%
10 years
65.12%
 

About: Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.

Employees: 2,400

0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 6 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

286% more first-time investments, than exits

New positions opened: 81 | Existing positions closed: 21

214% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 14

62% more call options, than puts

Call options by funds: $75.7M | Put options by funds: $46.8M

61% more funds holding

Funds holding: 96 [Q3] → 155 (+59) [Q4]

17% more funds holding in top 10

Funds holding in top 10: 6 [Q3] → 7 (+1) [Q4]

8.72% more ownership

Funds ownership: 25.2% [Q3] → 33.92% (+8.72%) [Q4]

18% less capital invested

Capital invested by funds: $2.12B [Q3] → $1.75B (-$374M) [Q4]

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$55
17%
downside
Avg. target
$61
8%
downside
High target
$70
5%
upside

6 analyst ratings

positive
50%
neutral
50%
negative
0%
Morgan Stanley
Tejas Savant
0 / 0 met price target
2%downside
$65
Overweight
Maintained
9 May 2025
Needham
Ryan MacDonald
35% 1-year accuracy
9 / 26 met price target
5%upside
$70
Buy
Reiterated
7 May 2025
BTIG
Mark Massaro
100% 1-year accuracy
3 / 3 met price target
10%downside
$60
Buy
Initiated
21 Apr 2025
Piper Sandler
David Westenberg
48% 1-year accuracy
15 / 31 met price target
17%downside
$55
Neutral
Maintained
4 Mar 2025
B of A Securities
Michael Ryskin
50% 1-year accuracy
1 / 2 met price target
10%downside
$60
Neutral
Maintained
3 Mar 2025

Financial journalist opinion

Based on 29 articles about TEM published over the past 30 days

Neutral
Business Wire
5 hours ago
Tempus Enters Multi-Year Strategic Collaboration With Boehringer Ingelheim to Advance Its Cancer Pipeline
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a new strategic collaboration to advance Boehringer Ingelheim's growing cancer pipeline. The new, multi-year collaboration builds on foundational work the two companies have conducted in the last few years, leveraging data and AI to further advance therapeutic research and development. Despite significant breakthroughs in the un.
Tempus Enters Multi-Year Strategic Collaboration With Boehringer Ingelheim to Advance Its Cancer Pipeline
Neutral
GlobeNewsWire
6 hours ago
Artificial Intelligence (AI) in Clinical Trials Market Insights, Competitive Landscape, and Forecasts Report 2025-2032 Featuring Key Players Such as TEMPUS, NetraMark, ConcertAI, AiCure, and Oracle
The AI in Clinical Trials Market is driven by the surge in chronic diseases and increased pharma collaborations. Valued at $1.35 billion in 2024, it aims to reach $3.33 billion by 2032. North America leads due to investment in R&D and numerous trials. The AI in Clinical Trials Market is driven by the surge in chronic diseases and increased pharma collaborations. Valued at $1.35 billion in 2024, it aims to reach $3.33 billion by 2032. North America leads due to investment in R&D and numerous trials.
Artificial Intelligence (AI) in Clinical Trials Market Insights, Competitive Landscape, and Forecasts Report 2025-2032 Featuring Key Players Such as TEMPUS, NetraMark, ConcertAI, AiCure, and Oracle
Neutral
Business Wire
21 hours ago
Tempus Announces Six Posters Accepted for Presentation at ISPOR 2025
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the presentation of six posters, including one oral presentation, at the 2025 annual meeting of the Professional Society for Health Economics and Outcomes Research (ISPOR), taking place May 13-16 in Montreal, Canada. Tempus researchers are showcasing scientific and clinical studies highlighting the impact of AI and real-world data.
Tempus Announces Six Posters Accepted for Presentation at ISPOR 2025
Neutral
24/7 Wall Street
1 day ago
Big Earnings Beats: 6 Stocks That Spiked After Reporting Results
We're winding down earnings season, and the old Wall Street adage that “earnings drive stock prices” continues to prove true.
Big Earnings Beats: 6 Stocks That Spiked After Reporting Results
Positive
Zacks Investment Research
5 days ago
These AI Stocks Posted Robust Results: Time to Buy?
Several AI-related stocks have posted robust results throughout the Q1 earnings cycle, a list that includes Palantir and Tempus AI. Given their results, it's impossible to deny the staying power of AI, which is still likely in its early innings.
These AI Stocks Posted Robust Results: Time to Buy?
Positive
MarketBeat
6 days ago
Tempus AI Stock: Time to Double Down or Cut and Run?
Tempus AI NASDAQ: TEM is an interesting AI story that operates a platform and library for diagnosis and drug discovery. The platform aids physicians by enabling personalized care for hard-to-treat illnesses and pharmaceutical companies like AstraZeneca NASDAQ: AZN, with advances in medicine impossible without computerized assistance.
Tempus AI Stock: Time to Double Down or Cut and Run?
Positive
Benzinga
6 days ago
Tempus AI Rallies After Q1 Beat, Analyst Notes AI-Driven Platform And Expanding Pharma Deals
JP Morgan analyst Rachel Vatnsdal reiterated the Neutral rating on Tempus AI, Inc. TEM on Wednesday, with a price forecast of $55.
Tempus AI Rallies After Q1 Beat, Analyst Notes AI-Driven Platform And Expanding Pharma Deals
Neutral
Seeking Alpha
1 week ago
Tempus AI, Inc. (TEM) Q1 2025 Earnings Call Transcript
Tempus AI, Inc. (NASDAQ:TEM ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Liz Krutoholow – Vice President-Investor Relations Eric Lefkofsky – Founder and Chief Executive Officer Jim Rogers – Chief Financial Officer Conference Call Participants Tejas Savant – Morgan Stanley Ryan MacDonald – Needham & Company Mark Schappel – Loop Capital Subbu Nambi – Guggenheim Daniel Brennan – TD Cowen Mark Massaro – BTIG Michael Ryskin – Bank of America Rachel Vatnsdal – JPMorgan Dan Arias – Stifel Operator Good day everyone. And thank you for standing by.
Tempus AI, Inc. (TEM) Q1 2025 Earnings Call Transcript
Neutral
Business Wire
1 week ago
Tempus Reports First Quarter 2025 Results
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2025. Revenue increased 75.4% year-over-year to $255.7 million in the first quarter of 2025 Quarterly gross profit increased 99.8% year-over-year, reaching $155.2 million with continued gross margin improvement in both Genomics and Data and services Announced multi-year, strategic.
Tempus Reports First Quarter 2025 Results
Neutral
24/7 Wall Street
1 week ago
TEMPUS (Nasdaq: TEM) Earnings: Live Coverage And What to Expect
Tempus AI (NASDAQ: TEM), a fast-rising player in clinical AI and health data infrastructure, will report its Q1 2025 earnings after the market closes today.
TEMPUS (Nasdaq: TEM) Earnings: Live Coverage And What to Expect
Charts implemented using Lightweight Charts™